Stay updated on Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in medical or healthcare-related publications or documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:28:06.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 02 14 has been updated to 05 29 on the webpage, indicating a recent change in the publication or documentation related to a study on Durvalumab with Tremelimumab as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC). This change likely reflects an update or new information regarding the study's progress or results in the medical and healthcare field.
    Difference
    0.7%
    Check dated 2024-05-30T09:46:48.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value on the webpage has been updated from 6 to 7, indicating a recent change in the number of relevant medical or healthcare-related publications or documentation. This update may reflect new information or additional studies being included in the database.
    Difference
    0.3%
    Check dated 2024-05-22T21:28:40.000Z thumbnail image
  8. Check
    39 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:47:39.000Z thumbnail image

Stay in the know with updates to Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.